Cellerant Therapeutics

About:

Cellerant Therapeutics is a clinical-stage company developing innovative cell- and antibody-based immunotherapies.

Twitter/X: cellerant

Top Investors: MPM Capital, Allen & Company, Camelot Venture Group, CX Venture Group, Novel Bioventures

Description:

Cellerant Therapeutics is a clinical-stage company developing innovative cell- and antibody-based immunotherapies for hematologic malignancies and other blood-related disorders. Cellerant’s Romyelocel-L is a universal cell therapy that does not require HLA matching intended to prevent bacterial and fungal infections during neutropenia. It was founded in 2003 and headquartered in San Carlos, California.

Total Funding Amount:

$110M

Estimated Revenue Range:

$10M to $50M

Headquarters Location:

San Carlos, California, United States

Founded Date:

2003-01-01

Contact Email:

info(AT)cellerant.com

Founders:

Irving L. Weissman

Number of Employees:

101-250

Last Funding Date:

2016-09-26

IPO Status:

Private

Industries: